SARS-CoV-2 causes COVID-19, a global health hazard. Recent identification of SARS-CoV-2 in CSF and frontal lobe slices confirms the virus's presence in neural tissue. This finding suggests a neurotherapeutic strategy for COVID-19 patients with underlying illnesses. It's time to consider COVID-19's neuroinvasiveness and the therapeutic use of large dosages of melatonin, which may alter SARS-immune CoV-2's response and neuroinflammation.
Dr. KK Aggarwal
President Heart Care Foundation of India and Group Editor in Chief MEDtalks
Dr. Shashank Joshi
President IAD, Past President ESI and API, Member, COVID -19 Task Force, Maharashtra
